445026389
19 Jun 2019
Switzerland Novartis continues to innovate in CML with long-term treatment-free remission results following Tasigna use and promising combination data with investigational compound asciminib ABL001, Switzerland
N/A
Banking, Finance, Insurance and Securities (BFIS) Tenders , Healthcare and Medical Tenders
Procurement News
Click for more details
If you have forgotten your User ID or Password, then please contact the TendersInfo Customercare by Email on customercare@tendersinfo.com.